 |
DAEJEON, South Korea, Nov. 16, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.
The clinical study was conducted in Australiafr...
Every four years, the FIFA World Cup becomes one of the largest commercial events on Earth. Billions of people watch match...
The latest job reductions at Nine Entertainment have again highlighted a question confronting every modern publisher. Can ...
Many Australians have encountered a familiar message while reading the news online. "Subscribe to continue reading." Whet...
When SpaceX first landed a Falcon 9 booster vertically on a floating drone ship, many experts desc...
Fremantle Ports has partnered with Byssal and DevelopmentWA to trial an innovative nature-based pilo...
After years of changing food trends—from low-fat to low-carbohydrate, detoxes and "superfoods"—it ...
The Korea Tourism Organization (KTO) has launched Korea Unlocks More of You, a new national campai...
The Korea Tourism Organization (KTO) has launched Korea Unlocks More of You, a new national campai...
Immigration has long helped shape modern Australia. New arrivals have contributed to the nation's...
Twenty-nine years ago, when Pauline Hanson's One Nation was officially formed in 1997, many politi...